Featured Post:
By: Bartu Ahiska, Ph.D.
Episodes 107-109 of this podcast explain how the EpiSwitch CiRT blood test stands out by evaluating a cancer patient's immune system readiness to work with checkpoint immunotherapy to fight their cancer.
Read PostSubscribe to receive our latest blog posts covering a wide range of topics, from groundbreaking discoveries to cutting-edge advancements and industry trends.
BioQuick News | Jan 25, 2024
GenomeWeb | Sep 1, 2023
Cancerworld | Feb 23, 2023
Oxford BioDynamics PLC (AIM: OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship products are the EpiSwitch CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. CiRT predicts how a patient will respond to immune checkpoint inhibitor therapies. PSE is a blood test that boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer.
OBD's proprietary EpiSwitch® platform harnesses 3D genomic regulation biomarkers to develop molecular diagnostic classifiers for numerous indications, including predicting response to therapy, patient prognosis, disease diagnosis, and residual disease monitoring. For more information, please visit myOBDX.com.
Learn About OBD